BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15744348)

  • 1. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
    van der Werff Ten Bosch J; Suciu S; Thyss A; Bertrand Y; Norton L; Mazingue F; Uyttebroeck A; Lutz P; Robert A; Boutard P; Ferster A; Plouvier E; Maes P; Munzer M; Plantaz D; Dresse MF; Philippet P; Sirvent N; Waterkeyn C; Vilmer E; Philippe N; Otten J
    Leukemia; 2005 May; 19(5):721-6. PubMed ID: 15744348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
    Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
    Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
    Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
    J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
    Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
    Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
    Link MP; Shuster JJ; Donaldson SS; Berard CW; Murphy SB
    N Engl J Med; 1997 Oct; 337(18):1259-66. PubMed ID: 9345074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
    Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
    J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T
    Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.